Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial

The results from the RATIFY trial (ClinicalTrials.gov: NCT00651261; CALGB 10603) showed that midostaurin combined with standard chemotherapy significantly improved outcomes in patients with FMS-like tyrosine kinase 3 (FLT3)–mutated acute myeloid leukemia (AML), compared with placebo. In this post ho...

全面介紹

Na minha lista:
書目詳細資料
發表在:Blood Adv
Main Authors: Voso, Maria Teresa, Larson, Richard A., Jones, Dan, Marcucci, Guido, Prior, Thomas, Krauter, Jürgen, Heuser, Michael, Lavorgna, Serena, Nomdedeu, Josep, Geyer, Susan M., Walker, Alison, Wei, Andrew H., Sierra, Jorge, Sanz, Miguel A., Brandwein, Joseph M., de Witte, Theo M., Jansen, Joop H., Niederwieser, Dietger, Appelbaum, Frederick R., Medeiros, Bruno C., Tallman, Martin S., Schlenk, Richard F., Ganser, Arnold, Amadori, Sergio, Cheng, Yuan, Chen, YinMiao, Pallaud, Celine, Du, Ling, Piciocchi, Alfonso, Ehninger, Gerhard, Byrd, John, Thiede, Christian, Döhner, Konstanze, Stone, Richard M., Döhner, Hartmut, Bloomfield, Clara D., Lo-Coco, Francesco
格式: Artigo
語言:Inglês
出版: American Society of Hematology 2020
主題:
Myeloid Neoplasia
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7556122/
https://ncbi.nlm.nih.gov/pubmed/33049054
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002904
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍